Mega Genomics (6667) Stock Overview

Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing, cancer screening, and other services in China. It offers general testing services comprising brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer's disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson's disease risk assessment; full-scale cancer risk assessment packages; and cardiovascular and cerebrovascular disease risk assessment packages. The company also provides advanced testing services, which include hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; andRNF180/Septin9 gastric cancer screening test, as well as executive testing services, such as personal whole genome test and whole-exome sequencing package for adults. The company serves health checkup centers, hospitals, and various other customers. Mega Genomics Limited was founded in 2016 and is headquartered in Beijing, China.